In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The main focus right now in the myeloma ...
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO. Outcomes of ...
Rutgers Robert Wood Johnson Medical School and collaborating institutions have found that overnutrition leads to insulin resistance and metabolic disorders through increased activity of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results